Cargando…

Optically Stimulated Luminescent Dosimetry for High Dose Rate Brachytherapy

Purpose: The objective was to determine whether optically stimulated luminescent dosimeters (OSLDs) were appropriate for in vivo measurements in high dose rate brachytherapy. In order to make this distinction, three dosimetric characteristics were tested: dose linearity, dose rate dependence, and an...

Descripción completa

Detalles Bibliográficos
Autores principales: Tien, Christopher Jason, Ebeling, Robert, Hiatt, Jessica R., Curran, Bruce, Sternick, Edward
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Research Foundation 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3412277/
https://www.ncbi.nlm.nih.gov/pubmed/22888476
http://dx.doi.org/10.3389/fonc.2012.00091
_version_ 1782239948980617216
author Tien, Christopher Jason
Ebeling, Robert
Hiatt, Jessica R.
Curran, Bruce
Sternick, Edward
author_facet Tien, Christopher Jason
Ebeling, Robert
Hiatt, Jessica R.
Curran, Bruce
Sternick, Edward
author_sort Tien, Christopher Jason
collection PubMed
description Purpose: The objective was to determine whether optically stimulated luminescent dosimeters (OSLDs) were appropriate for in vivo measurements in high dose rate brachytherapy. In order to make this distinction, three dosimetric characteristics were tested: dose linearity, dose rate dependence, and angular dependence. The Landauer nanoDot™ OSLDs were chosen due to their popularity and their availability commercially. Methods: To test the dose linearity, each OSLD was placed at a constant location and the dwell time was varied. Next, in order to test the dose rate dependence, each OSLD was placed at different OLSD-to-source distances and the dwell time was held constant. A curved geometry was created using a circular Accuboost(®) applicator in order to test angular dependence. Results: The OSLD response remained linear for high doses and was independent of dose rate. For doses up to 600 cGy, the linear coefficient of determination was 0.9988 with a response of 725 counts per cGy. The angular dependence was significant only in “edge-on” scenarios. Conclusion: OSLDs are conveniently read out using commercially available readers. OSLDs can be re-read and serve as a permanent record for clinical records or be annealed using conventional fluorescent light. Lastly, OSLDs are produced commercially for $5 each. Due to these convenient features, in conjunction with the dosimetric performance, OSLDs should be considered a clinically feasible and attractive tool for in vivo HDR brachytherapy measurements.
format Online
Article
Text
id pubmed-3412277
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Frontiers Research Foundation
record_format MEDLINE/PubMed
spelling pubmed-34122772012-08-10 Optically Stimulated Luminescent Dosimetry for High Dose Rate Brachytherapy Tien, Christopher Jason Ebeling, Robert Hiatt, Jessica R. Curran, Bruce Sternick, Edward Front Oncol Oncology Purpose: The objective was to determine whether optically stimulated luminescent dosimeters (OSLDs) were appropriate for in vivo measurements in high dose rate brachytherapy. In order to make this distinction, three dosimetric characteristics were tested: dose linearity, dose rate dependence, and angular dependence. The Landauer nanoDot™ OSLDs were chosen due to their popularity and their availability commercially. Methods: To test the dose linearity, each OSLD was placed at a constant location and the dwell time was varied. Next, in order to test the dose rate dependence, each OSLD was placed at different OLSD-to-source distances and the dwell time was held constant. A curved geometry was created using a circular Accuboost(®) applicator in order to test angular dependence. Results: The OSLD response remained linear for high doses and was independent of dose rate. For doses up to 600 cGy, the linear coefficient of determination was 0.9988 with a response of 725 counts per cGy. The angular dependence was significant only in “edge-on” scenarios. Conclusion: OSLDs are conveniently read out using commercially available readers. OSLDs can be re-read and serve as a permanent record for clinical records or be annealed using conventional fluorescent light. Lastly, OSLDs are produced commercially for $5 each. Due to these convenient features, in conjunction with the dosimetric performance, OSLDs should be considered a clinically feasible and attractive tool for in vivo HDR brachytherapy measurements. Frontiers Research Foundation 2012-08-06 /pmc/articles/PMC3412277/ /pubmed/22888476 http://dx.doi.org/10.3389/fonc.2012.00091 Text en Copyright © 2012 Tien, Ebeling III, Hiatt, Curran and Sternick. http://www.frontiersin.org/licenseagreement This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.
spellingShingle Oncology
Tien, Christopher Jason
Ebeling, Robert
Hiatt, Jessica R.
Curran, Bruce
Sternick, Edward
Optically Stimulated Luminescent Dosimetry for High Dose Rate Brachytherapy
title Optically Stimulated Luminescent Dosimetry for High Dose Rate Brachytherapy
title_full Optically Stimulated Luminescent Dosimetry for High Dose Rate Brachytherapy
title_fullStr Optically Stimulated Luminescent Dosimetry for High Dose Rate Brachytherapy
title_full_unstemmed Optically Stimulated Luminescent Dosimetry for High Dose Rate Brachytherapy
title_short Optically Stimulated Luminescent Dosimetry for High Dose Rate Brachytherapy
title_sort optically stimulated luminescent dosimetry for high dose rate brachytherapy
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3412277/
https://www.ncbi.nlm.nih.gov/pubmed/22888476
http://dx.doi.org/10.3389/fonc.2012.00091
work_keys_str_mv AT tienchristopherjason opticallystimulatedluminescentdosimetryforhighdoseratebrachytherapy
AT ebelingrobert opticallystimulatedluminescentdosimetryforhighdoseratebrachytherapy
AT hiattjessicar opticallystimulatedluminescentdosimetryforhighdoseratebrachytherapy
AT curranbruce opticallystimulatedluminescentdosimetryforhighdoseratebrachytherapy
AT sternickedward opticallystimulatedluminescentdosimetryforhighdoseratebrachytherapy